Quantum Blockchain says Sipiem enforcement auction halted as defendant enters court-supervised liquidation
Bitget2026/10/06 13:00Quantum Blockchain Technologies’ Sipiem-related fund recovery case in Italy shifted into a court-supervised liquidation for the defendant. The liquidation halts the separate enforcement timetable for a real estate asset; an auction set for Oct. 21, 2026 will not proceed. QBT expects a longer recovery timeline, though the Venice Court of Appeal judgment remains in force. Clear Leisure 2017 retains creditor status on damages exceeding EUR 6 million, with interest, inflation compensation, legal costs. The liquidation brings the defendant’s broader estate into the process; concealment of assets can trigger criminal consequences under Italian law. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum Blockchain Technologies plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610060859PR_NEWS_PRUKDSCX_0084) on October 06, 2026, and is solely responsible for the information contained therein.
- Quantum Blockchain Technologies’ Sipiem-related fund recovery case in Italy shifted into a court-supervised liquidation for the defendant.
- The liquidation halts the separate enforcement timetable for a real estate asset; an auction set for Oct. 21, 2026 will not proceed.
- QBT expects a longer recovery timeline, though the Venice Court of Appeal judgment remains in force.
- Clear Leisure 2017 retains creditor status on damages exceeding EUR 6 million, with interest, inflation compensation, legal costs.
- The liquidation brings the defendant’s broader estate into the process; concealment of assets can trigger criminal consequences under Italian law.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
JPMorgan raises AbbVie target price to $300